id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-3341-0003,FDA,FDA-2016-E-3341,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2016-12-06T05:00:00Z,2016,12,2016-12-06T05:00:00Z,,2016-12-06T20:23:03Z,,0,0,09000064823e5906
FDA-2016-E-3341-0001,FDA,FDA-2016-E-3341,Patent Extension Application from Wenderoth Lind & Ponack LLP  ( on behalf of RaQualia Pharma Inc),Other,Application,2016-10-17T04:00:00Z,2016,10,2016-10-17T04:00:00Z,,2016-10-17T17:26:01Z,,0,0,09000064822f525e
FDA-2016-E-3341-0002,FDA,FDA-2016-E-3341,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2016-10-17T04:00:00Z,2016,10,2016-10-17T04:00:00Z,,2016-10-17T17:29:10Z,,0,0,09000064822f5260